XV 459

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341471

CAS#: 170902-52-0

Description: XV 459 is a biochemical.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-07. Prices are subject to change without notice.

XV 459 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 341471
Name: XV 459
CAS#: 170902-52-0
Chemical Formula: C20H27N5O6
Exact Mass: 433.1961
Molecular Weight: 433.465
Elemental Analysis: C, 55.42; H, 6.28; N, 16.16; O, 22.15

Synonym: XV 459; XV459; X 459.

IUPAC/Chemical Name: L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, (R)-


InChi Code: InChI=1S/C20H27N5O6/c1-2-3-8-30-20(29)24-16(19(27)28)11-23-17(26)10-14-9-15(25-31-14)12-4-6-13(7-5-12)18(21)22/h4-7,14,16H,2-3,8-11H2,1H3,(H3,21,22)(H,23,26)(H,24,29)(H,27,28)/t14-,16+/m1/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Mousa SA, Ahmad S. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Am J Hematol. 2007 Apr;82(4):276-82. PubMed PMID: 17039513.

2: Pieniaszek HJ Jr, Davidson AF, Walton HL, Pinto DJ, Olson RE, Reilly TM, Barrett YC. A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma. J Pharm Biomed Anal. 2003 Jan 1;30(5):1441-9. PubMed PMID: 12467915.

3: Fossler MJ, Ebling WF, Ma S, Kornhauser D, Mondick J, Barrett JS, Garner D, Quon CY, Pieniaszek HJ Jr. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers. J Clin Pharmacol. 2002 Dec;42(12):1326-34. PubMed PMID: 12463727.

4: Pieniaszek HJ Jr, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):738-53. PubMed PMID: 12092741.

5: Mutlib AE, Diamond S, Shockcor J, Way R, Nemeth G, Gan L, Christ DD. Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor. Xenobiotica. 2000 Nov;30(11):1091-110. PubMed PMID: 11197070.

6: Barrett JS, Yu J, Kapil R, Padovani P, Brown F, Ebling WF, Corjay MH, Reilly TM, Bozarth JM, Mousa SA, Pieniaszek HJ Jr. Disposition and exposure of the fibrinogen receptor antagonist XV459 on alphaIIBbeta3 binding sites in the guinea pig. Biopharm Drug Dispos. 1999 Sep;20(6):309-18. PubMed PMID: 10701702.

7: Mousa SA, Kapil R, Mu DX. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2535-41. PubMed PMID: 10521384.

8: Mousa SA, Mu DX, Hussain MA. Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755. Thromb Res. 1998 Nov 1;92(3):115-24. PubMed PMID: 9806363.

9: Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJ, Slee AM, Reilly TM, Friedman PA. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther. 1998 Sep;286(3):1277-84. PubMed PMID: 9732389.

10: Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res. 1998 Mar 15;89(6):271-9. PubMed PMID: 9669749.

11: Mousa SA, Bozarth J, Youssef A, Levine B. Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates. Thromb Res. 1998 Mar 1;89(5):217-25. PubMed PMID: 9645915.

12: Hussain MA, Aungst BJ, Kapil R, Mousa SA. Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability. J Pharm Sci. 1997 Dec;86(12):1358-60. PubMed PMID: 9423145.

13: Mousa SA, Forsythe M, Lorelli W, Bozarth J, Xue CB, Wityak J, Sielecki TM, Olson RE, DeGrado W, Kapil R, Hussain M, Wexler R, Thoolen MJ, Reilly TM. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron Artery Dis. 1996 Oct;7(10):767-74. PubMed PMID: 8970768.